MannKind

MannKind Corp. operates as a biopharmaceutical company. It focuses on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MannKind reports strong Q4 earnings, eyes revenue growth opportunities

MannKind's strong financial performance in Q4 2022, driven by revenue growth and improved margins, positions the company for future success.
While challenges exist in healthcare innovation and regulatory processes, MannKind's focus on internal innovation and revenue diversification presents growth opportunities.
Opportunities in collaborations, inhaled therapeutics, and data-driven healthcare outcomes offer avenues for MannKind's future expansion and profitability.
Maintaining financial stability, driving revenue growth, and exploring new product opportunities are key strategies for MannKind's long-term success.

MannKind reports strong Q1 performance, eyes revenue growth opportunities

MannKind's Q1 2023 earnings call highlighted strong performance in royalty revenue, endocrine business, and liquidity position. Challenges include maintaining growth amidst competition, while opportunities lie in revenue growth and strategic collaborations. Overall, MannKind's positive outlook is supported by its pipeline progress and focus on shareholder value.

MannKind achieves first operating income, eyes international expansion for growth

MannKind's Q2 performance reflects significant financial milestones, with revenue growth, operating income, and strong gross margins showcasing operational efficiency and progress towards profitability.
While facing challenges such as trial costs and regulatory requirements, the company's strategic strengths in product expansion, R&D investments, and international partnerships position it for long-term growth.
Opportunities in strong patient demand, international market expansion, orphan lung areas, and product growth present avenues for revenue diversification and sustained performance.
Overall, MannKind's focus on innovation, financial sustainability, and market expansion sets a positive trajectory for future growth and profitability.

MannKind achieves first profitable quarter with strong revenue growth

MannKind's Q3 marked a profitable quarter with significant revenue growth and operational improvements.
Strengths include revenue diversification, margin enhancements, and promising trial progress.
Challenges lie in stabilizing V-Go revenue, fluctuating earnings, and trial design adjustments.
Opportunities include upcoming milestones, market leverage, and Medicare changes for growth.

MannKind reports record 2023 revenues, eyes growth opportunities in 2024

MannKind had a strong financial performance in 2023, with a focus on debt repayment, clinical trials, and shareholder value in 2024. Innovation in powders and NTM asset, along with strategic positioning and sales force optimization, offer growth potential.

MannKind reports record revenue in Q2 2024 earnings call

MannKind's Q2 2024 performance reflects strong revenue growth and progress on key products.
While facing challenges in IP protection and manufacturing capacity, the company maintains a healthy cash position.
Opportunities lie in upcoming milestones and market expansion, with a focus on enhancing financial performance.

MannKind reports record revenue, shifts focus to growth strategies

MannKind delivered strong financial performance, focusing on growth and innovation in its product portfolio. While transitioning Afrezza's mindset poses challenges, strategic investments and market expansion present promising opportunities for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

WESTLAKE VILLAGE, Calif., July 29, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes (T1D) for a one-of-a-kind experience with local youth and families as part of Music City Grand Prix week.

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-Karts With Local Youth On Wednesday, August 4th

MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MannKind (MNKD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Anavex Life Sciences

Bionano Genomics

GT Biopharma Inc

Mogo

Qumu Corp.

Comscore Inc.

Current & Former Penny Stocks With High Marks From Analysts Right Now. The post 7 Hot Penny Stocks Analysts Like To Watch In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Hot Penny Stocks Analysts Like To Watch In 2021

The stock price of MannKind Corporation (NASDAQ: MNKD) increased by over 10% pre-market. This is why it happened.

MNKD Stock Price Increases Over 10% Pre-Market: Why It Happened

WESTLAKE VILLAGE, Calif., June 28, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) appreciates the recent efforts of the Centers for Medicare and Medicaid Services (CMS) in conjunction with the Medicare Administration Contractors (MACs) to implement a policy change to the Local Coverage Determination (LCD) L33822, allowing the approval to Medicare patients living with diabetes to select both Afrezza® and Continuous Glucose Monitors (CGMs).

Policy Change Allows Approval For Medicare Patients Living With Diabetes To Use Both Afrezza® And Continuous Glucose Monitoring Devices Beginning July 18

WESTLAKE VILLAGE, Calif., June 25, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD), which focuses on the development of innovative medicines for patients with endocrine and orphan lung diseases, will present two posters at the American Diabetes Association's virtual 81st Scientific Sessions, June 25-29.

MannKind Presents Two Posters At American Diabetes Association's Virtual 81st Scientific Sessions, June 25-29

United Therapeutics

DANBURY, Conn., June 16, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) and United Therapeutics Corporation (Nasdaq: UTHR) reached a major milestone today with the announcement that the U.S. Food and Drug Administration (FDA) accepted for priority review of the New Drug Application (NDA) for Tyvaso DPI™ (inhaled treprostinil) for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI™ With New Drug Application Acceptance From The FDA

The stock price of MannKind Corporation (NASDAQ: MNKD) increased by over 7% pre-market. This is why it happened.

MNKD Stock Price Increases Over 7% Pre-Market: Why It Happened

MannKind Corporation (NASDAQ: MNKD) and United Therapeutics Corporation (NASDAQ: UTHR) have announced that the FDA has accepted for review the marketing application of Tyvaso DPI (inhaled treprostinil). Under priority review status, the application seeks approval to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

MannKind - United Therapeutics' Formulated Treprostinil Under FDA Review For Pulmonary Hypertension

MannKind Corporation (MNKD) Management Presents at Lytham Partners Summer 2021 Investor Conference (Transcript)

MannKind will conduct formulation and preclinical studies  of a new chemical entity owned by Thirona

MannKind and Thirona Bio Join Forces to Evaluate Potential Inhaled Therapy for Fibrotic Lung Diseases

WESTLAKE VILLAGE, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will present at the Lytham Partners Summer 2021 Investor Conference on Monday, June 14, 2021 at 11:45 AM (ET).

MannKind Corporation at the Lytham Partners Summer 2021 Investor Conference

WESTLAKE VILLAGE, Calif., June 3, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD), which focuses on the development of innovative medicines for patients with endocrine and orphan lung diseases, announced today that it will present a poster [Abstract #654 / Topic AS09 – New Insulin Delivery Systems: Inhaled, Transdermal, Implanted Devices] at the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2021) to be held virtually, June 2-5.

MannKind Announces Data Presentation At 14th International Conference On Advanced Technologies & Treatments For Diabetes (ATTD 2021) To Be Held Virtually June 2-5

WESTLAKE VILLAGE, Calif. and INDIANAPOLIS, May 20, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes (T1D) for a one-of-a-kind experience with 20 local youth and families to kick off Indy 500 week.

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-karts With Local Youth On Tuesday, May 25th

MannKind Corporation's (MNKD) CEO Michael Castagna Presents at 2021 RBC Capital Markets Global Healthcare Conference (Transcript)

Elys Game Technology, Corp.

Nokia

New York Mortgage Trust

trivago

Analysts expect big moves from these penny stocks. The post Best Penny Stocks To Buy According To Analysts, 1 With 95% Target appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy According To Analysts, 1 With 95% Target

MannKind Corporation (MNKD) CEO Michael Castagna on Q1 2021 Results - Earnings Call Transcript

WESTLAKE VILLAGE, Calif. and INDIANAPOLIS, May 13, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) is revved up to announce a partnership for the 2021 season with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes (T1D) and will help raise awareness about diabetes and innovative management options.

MannKind Announces Partnership With Type 1 Diabetes IndyCar Driver Conor Daly

Shares of MannKind (NASDAQ:MNKD) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 25.00% over the past year to ($0.05), which missed the estimate of ($0.04).

MannKind: Q1 Earnings Insights

Conference Call to Begin Today at 5:00 PM ET

MannKind Corporation Reports 2021 First Quarter Financial Results

MannKind (NASDAQ:MNKD) announces its next round of earnings this Wednesday, May 12. Here is Benzinga's everything-that-matters guide for this Wednesday's Q1 earnings announcement.

A Preview Of MannKind's Earnings

WESTLAKE VILLAGE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 at 4:15 pm (ET). Interested parties can access a link to the webcast from the Events & Presentations section of the Company's website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.

MannKind Corporation to Participate in 2021 RBC Capital Markets Global Healthcare Conference

Earnings Preview: MannKind (MNKD) Q1 Earnings Expected to Decline

WESTLAKE VILLAGE, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that on April 22, 2021 it and MidCap Financial Trust, as agent, entered into an amendment of the credit and security agreement dated August 6, 2019 (the “MidCap Credit Facility”). In addition, MannKind and Mann Group, LLC entered into an amendment of the terms of the Mann Group convertible note and repaid in full outstanding amounts under the Mann Group non-convertible note on April 22, 2021. In connection with these transactions, MannKind reduced its outstanding amount of indebtedness, yet retained flexibility to borrow additional amounts under tranche 3 of the MidCap Credit Facility, which is available to borrow until June 30, 2022, subject to the satisfaction of certain milestone conditions associated with Tyvaso DPI™.

MannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche

Following Afrezza®, Tyvaso DPI is the second compound formulated with Technosphere® technology to be reviewed by FDA Following Afrezza®, Tyvaso DPI is the second compound formulated with Technosphere® technology to be reviewed by FDA

News for MannKind Stock (MNKD)